The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185–8. , .
et al. Matrix metalloproteinase in cancer: from new function to improved inhibition strategies. Int J Dev Biol 2004; 48: 411–24. , ,
Colorectal cancer and non-steroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1–20. , .
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336–40. , , .
et al. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004; 10: 7727–37. , ,
Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125–40. .
et al. Prostaglandin E2 increases growth and mobility of colorectal carcinoma cells. J Biol Chem 2000; 276: 18075–81. , ,
Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278: 35451–7. , , , .
et al. Prostaglandins promote colon cancer cell invasion: signaling by cross-talk between distinct growth factor receptors. FASEB J 2003; 17: 1640–7. , ,
Prostaglandin E receptor. J Biol Chem 2008; 282: 11613–7. , .
et al. Host prostaglandin E2–EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003; 197: 221–32. , ,
Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinoma. J Surg Oncol 2002; 80: 105–10. , , .
PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 2008; 111: 260–70. , , .
et al. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 2005; 26: 753–61. , ,
et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: an analysis using specific agonists for respective EPs. Endocrinology 2000; 141: 1554–9. , ,
et al. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005; 26: 271–9. , ,
et al. Host stromal bradikinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res 2004; 64: 5178–85. , ,
et al. Recruitment of a prostaglandin E receptor subtype, EP3-expressing bone marrow cells is crucial in wound-induced angiogenesis. Am J Pathol 2006; 169: 1458–72. , ,
Role of metalloproteinase (MMPs) in colorectal cancer. Cancer Metastasis Review 2004; 23: 101–17. , .
Matrix metalloproteinase target protease-activated receptors on the tumor cell surface. Cancer Cell 2002; 7: 207–8. .
MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2002; 2: 251–2. , .
Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in the lung cancer. FEBS Lett 2001; 508: 365–8. , , .
et al. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol 2008; 3: 117–24. , ,
et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000; 60: 4629–37. , ,
et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820–7. , ,
et al. Bone marrow-derived EP3-expression stromal cells enhance tumor-associated angiogenesis and tumor growth. Biochem Biophys Res Commun 2009; 382: 720–5. , ,
et al. Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. Jpn J Pharmacol 2001; 87: 181–8. , ,
et al. Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis. BBRC 2004; 321: 337–44. , ,
et al. Diverse effects of zinc on NF-κB and AP-1 transcription factors: implication for prostate cancer progression. Carcinogenesis 2006; 27: 1980–90. , ,
et al. Expression of cyclooxygenase-2 promotes the release of matrix metaloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 2001; 33: 860–7. , ,
et al. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and metalloproteinase. J Clin Invest 1997; 99: 894–900. , ,
et al. Prostaglandins E2 and E1 inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts. Mediation by cyclic-AMP signalling pathway. Lab Invest 1994; 71: 270–8. , ,
et al. Prostaglandin E2 promotes integrin αvβ3-dependent endothelial cell adhesion, Rac-activation and spreading through cAMP/PKA-dependent signaling. J Biol Chem 2002; 277: 45838–46. , ,